Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Dynavax Technologies  (Stock symbol: DVAX )

2929 7th Street #100
Berkeley, CA 94710
USA
(510)-848-5100
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Peggy V. Phillips (Immunex Former COO) Francis R. Cano (Cano Biotech President) Daniel L. Kisner (Aberdare Ventures Former Partner) Nat Ricciardi (Pfizer SVP) Julie Eastland (BioClin Therapeutics) Andrew Hack (Bain Capital Ventures Managing Director) Brent MacGregor (Seqirus Former SVP Commercial Operations) Arnold L. Oronsky (InterWest Partners General Partner)
Former outside board: Dino Dina (Dynavax Technologies Former President/CEO);  Stanley A. Plotkin (University of Pennsylvania Professor Emeritus) Nancy L. Buc (Buc & Beardsley Partner) Louis C. Bock (Scale Venture Partners) David M. Lawrence (Kaiser Foundation Former CEO/Chairman) Laura A. Brege (Nodality CEO/President) Mark Kessel (Symphony Capital Partner) Dennis A. Carson (noted researcher) Denise M. Gilbert (Entigen Former CEO) Daniel S. Janney (Alta Partners);  Jan Leschly (Care Capital);  Jeffrey Sollender (Forward Ventures)
Company

Business description: Dynavax Technologies Corporation (Nasdaq: DVAX) is a fully-integrated biopharmaceutical company focused on leveraging the power of the body’s innate and adaptive immune responses through Toll-like Receptor (TLR) stimulation. Dynavax develops, and commercializes novel vaccines. We are committed to a rigorous approach to drug development in the field of TLR biology so that we may help physicians and patients address unmet needs. Our vision and work ethic are guided by the collective ideals underpinning our corporate values, and these form the basis of our company culture.
Partners include: AstraZeneca GlaxoSmithKline ;  Aventis Pasteur;  Berna Biotech;  Deerfield Management ;  Stallergenes;  Triangle Pharmaceuticals
Capital

Rounds: 5
Recent Fundings: Oct 2012   Sep 2003
Capital raised: 88.8M
Last Round: 6.0M
Ownership: Public  
Stock Symbol: DVAX
Corporate investors: Astra Zeneca SightLine Partners

Last Tweets


 

Last Mentions


Overview
Record updated: Feb 2021
Sector: Biotech
Year Founded: 1996
Headcount: 201-300 as of Feb 2021
Rounds: 5
Recent Fundings: Oct 2012   Sep 2003
Capital Raised: 88.8M
Last Round: 6.0M
Ownership: Public  
Stock Symbol: DVAX